精密科学（EXAS）今日盘中股价大涨13.02%，延续了盘前的强劲涨势。这一显著涨幅主要源于公司发布的2025年第一季度财务报告表现优异，特别是营收大幅超出市场预期。
根据公司公布的财报，精密科学2025年第一季度实现营收7.07亿美元，同比增长10.9%，不仅高于分析师预期的6.894亿美元，还显著超过上一季度的6.375亿美元。这一强劲的营收增长表明公司业务持续扩张，市场需求旺盛。尽管每股亏损0.54美元未能达到分析师预期的0.38美元，但相比上一季度的0.60美元已有明显改善，显示公司正在逐步缩小亏损。
精密科学此次财报的亮眼表现，尤其是营收大幅超出预期，成功提振了投资者信心。盘中股价的强劲上涨反映出市场对公司未来发展前景持积极态度，预计公司在生物医疗诊断领域的领先地位将进一步巩固。然而，投资者仍需关注公司在提高盈利能力方面的进展，以及未来几个季度的业绩表现。分析师对该公司保持乐观态度，平均评级为"买入"，12个月目标价中位数为68.34美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.